New drug hope for painful hand and foot pustules
NCT ID NCT07000630
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested the drug deucravacitinib in people with moderate-to-severe palmoplantar pustulosis, a skin condition causing painful pustules on the palms and soles. The study planned to enroll 25 participants who would take the drug daily for 16 weeks, but it was terminated early with only 3 participants. Researchers aimed to see if the drug could reduce pustules and improve quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Deucravacitinib
What this could lead to
If it works, this could point toward a new oral treatment option for palmoplantar pustulosis, a chronic skin condition with limited therapies.
What could go wrong
The trial was terminated early with only 3 participants, so results are very limited. It is a small, non-randomized study, and the drug may not prove effective or safe in larger groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, 100034, China